Sales & Marketing News | pharmaphorum

News

Alkermes offers more for Avadel after Lundbeck bid

Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior.

News

Bayer gets EU approval for menopause drug Lynkuet

Bayer now has approval on both sides of the Atlantic for Lynkuet, with the EU backing it for symptoms caused by both menopause and breast cancer.

News

Representation on cellular level of lymphoma

Approvals extend use of Roche, AbbVie drugs in lymphoma

Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly.

News

US vulnerable to China's API dominance, says report

China has such a dominant position in pharmaceutical ingredient production that there is a risk it will weaponise access, says a Congressional report.

News

Novo Nordisk cuts Wegovy price ahead of TrumpRx launch

Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide.

News

Sandoz launches first biosimilar Tysabri in US

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

Alkermes offers more for Avadel after Lundbeck bid

Bayer gets EU approval for menopause drug Lynkuet

Approvals extend use of Roche, AbbVie drugs in lymphoma

US vulnerable to China's API dominance, says report

Novo Nordisk cuts Wegovy price ahead of TrumpRx launch

Sandoz launches first biosimilar Tysabri in US

UK's Mission divests kidney drug to Dimerix for $292m

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks